

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



3SBIO INC.

三生制药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of 3SBio Inc. (the “**Company**” together with its subsidiaries, the “**Group**”) on a voluntary basis. Reference is also made to the Company’s announcement dated November 20, 2015 with respect to the Group’s acquisition of further equity interests in CP Guojian (the “**Announcement**”) and the announcement dated December 11, 2015 with respect to a delay in the dispatch of the circular with respect to the acquisitions (the “**Circular**”) described in the Announcement. Capitalized terms used in this announcement shall have the same meanings as set out in the Announcement unless otherwise defined.

As confirmed by Shanghai Lansheng Corporation (上海蘭生股份有限公司) (“**Lansheng Corporation**”, the shares of which are listed on the Shanghai Stock Exchange under the stock code 600826), Shanghai Hongshang, a non-wholly owned subsidiary of the Company, was the only intended transferee for (i) the 0.73% equity interest in CP Guojian owned by Lansheng Corporation, (ii) the 34.65% equity interest in Lansheng Guojian owned by Lansheng Corporation and (iii) the 3.85% equity interest in Lansheng Guojian owned by Shanghai Lansheng (Group) Corporation (上海蘭生(集團)有限公司) (“**Lansheng Group**”) (collectively, the “**Equity Interests**”) put up for sale via the Shanghai United Assets and Equity Exchange (上海聯合產權交易所). As of the date of this announcement, the Group collectively controls an approximately 53.64% equity interest in CP Guojian.

Shanghai Hongshang is expected to proceed with signing equity transfer agreements with Lansheng Corporation and Lansheng Group. The Company will announce further details once the relevant equity transfer agreements are duly executed and, as the transactions will be aggregated with the acquisitions set out in the Announcement pursuant to Rule 14.22 of the Listing Rules, will include all relevant details and other information required by the Listing Rules in the Circular as required.

REASONS AND BENEFITS OF THE BIDDING

The purpose of the bidding is to acquire further direct and indirect equity interests in CP Guojian. For further details of the reasons and benefits for the acquisition of CP Guojian, please refer to the Announcement.

GENERAL INFORMATION

The Company is a leading biotechnology company in the People's Republic of China. The Group has extensive expertise in developing, manufacturing and marketing biopharmaceuticals.

Shanghai Hongshang is an investment holding company.

Lansheng Corporation is a company primarily engaged in the import and export of goods and technologies.

Lansheng Group is a company primarily engaged in the operation and management of state-owned assets and international trades.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Lansheng Corporation, Lansheng Group and their ultimate beneficial owners are not connected persons or associates of connected persons of the Company under the Listing Rules and are independent of the connected persons of the Company.

As definitive equity transfer agreements in respect of the Group's acquisition of the Equity Interests are yet to be signed, there can be no assurance that the acquisition of the Equity Interests will proceed and that any forward-looking statements regarding the business developments of the Group or any of the other matters set out herein will materialize. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein.

By order of the Board
3SBio Inc.
Mr. LOU Jing
Chairman

Hong Kong, January 19, 2016

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive Directors; Mr. LIU Dong and Mr. LV Dong as non-executive Directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive Directors.